Benzinga | Nov 19, 2021 07:04AM EST

SVB Leerink Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $28

SVB Leerink analyst Daina Graybosch maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target from $29 to $28.